Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor

(2015) David M. Gershenson et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver

(2014) C. Emmanuel et al.   CLINICAL CANCER RESEARCH

KRAS(but notBRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma

(2013) Yvonne T Tsang et al.   JOURNAL OF PATHOLOGY

Association ofKRASandEGFRmutations with survival in patients with advanced lung adenocarcinomas

(2012) Melissa L. Johnson et al.   CANCER

BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

(2012) Rachel N. Grisham et al.   CANCER

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

Low-grade serous primary peritoneal carcinoma

(2011) Kathleen M. Schmeler et al.   GYNECOLOGIC ONCOLOGY

BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas

(2010) Kwong-Kwok Wong et al.   AMERICAN JOURNAL OF PATHOLOGY

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

(2010) Silvestre Vicent et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

(2009) J Souglakos et al.   BRITISH JOURNAL OF CANCER

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

(2009) Nathalie Dhomen et al.   CANCER CELL